Profile photo

Urologic Oncology With Christopher Wallis, MD, PhD, FRCSC

Urology

Dr. Wallis is a urologic oncologist at the University of Toronto and Mount Sinai Hospital/University Health Network. He completed his Society of Urologic Oncology-accredited fellowship training at Vanderbilt University Medical Center. His clinical work and research are focused on the care of patients with prostate, kidney, bladder, and testis cancer.

Post-ASCO-GU 2025 Insights: Take 2

Dear readers,

Welcome back to the second in our series highlighting the incredible advances we’ve seen in advanced bladder cancer recently. While there has been a deserved focus on EV and immunotherapeutic approaches, novel mechanisms, including ADCs with novel targets, offer great promise.

Best,

Christopher Wallis, MD

Articles
  • Mashup Score: 14
    The View On GU - 16 day(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of theviewongu
      theviewongu

      🚨Episode 18 is out! The second episode in our mini-series from @ASCO GU focuses on #BladderCancer. Dr. @lalaniMD & Dr. @WallisCJD talk about CheckMate 247, a Phase 3 clinical trial using adjuvant nivolumab in resected urothelial cancer. Check it out at https://t.co/JkBLV6bggF! https://t.co/A4aVyD1xr2

  • Mashup Score: 130
    • Profile photo of DrYukselUrun
      DrYukselUrun

      Not all ADCs are created equal! Di (Maria) Jiang, MD
      Mechanism of action impacts efficacy & toxicity—target, linker, and payload matter. How do we optimize sequencing for #bladdercancer treatment?
      #GU25 #oncology #cancer @asco @oncoalert @MikeSerzanMD @drenriquegrande… https://t.co/CKgBiMvw7I https://t.co/y9pK183Yj4

      Read the original tweet here

    Tweet Tweets with this article
    • Profile photo of walliscjd
      walliscjd

      For those trying to keep up to speed, Dr. Maria Jiang provided a fantastic overview of ADCs in bladder cancer at the recent ASCO-GU 2025 meeting. Check out highlights here.

  • Mashup Score: 29
    • Profile photo of JasonBrownMDPhD
      JasonBrownMDPhD

      #GU25 Perioperative Trial w Disitimab Vedotin + Toripalimab

      🧪 HER2 positive (1+/2+/3+ IHC)

      ‼️ 63.6% pCR

      👏 92.5% 12 mo EFS

      ⚡️ 21% peripheral neuropathy

      🗞️ HER2 is promising target

      🔜 With effective ADCs, bladder preservation studies needed

      @OncoAlert @BladderCancerUS https://t.co/WgrA0811SO

      Read the original tweet here

    Tweet Tweets with this article
    • Profile photo of walliscjd
      walliscjd

      Also presented at ASCO-GU 2025, we saw early phase 2 data for the use of the HER-2 targeting ADC disitimab vedotin with the immune checkpoint inhibitor toripalimab in the peri-operative setting. Better peri-operative systemic therapy clearly offers the opportunity for novel approaches to bladder sparing.

  • Mashup Score: 13
    • Profile photo of TiansterZhang
      TiansterZhang

      @MattMilowsky with updated #Checkmate274 trial – adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing @ALLIANCE_org #MODERN trial! @ASCO #GU25 https://t.co/aJahmjtv41

      Read the original tweet here

    Tweet Tweets with this article
    • Profile photo of walliscjd
      walliscjd

      ASCO-GU 2025 finally brought the OS data for CheckMate-274. As Dr Milowsky reported, adjuvant nivolumab was associated with a 30% improvement in overall survival (HR 0.70, 95% CI 0.55-0.90) in resected muscle invasive disease.